Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.

Tlemsani C, Pécuchet N, Gruber A, Laurendeau I, Danel C, Riquet M, Le Pimpec-Barthes F, Fabre E, Mansuet-Lupo A, Damotte D, Alifano M, Luscan A, Rousseau B, Vidaud D, Varin J, Parfait B, Bieche I, Leroy K, Laurent-Puig P, Terris B, Blons H, Vidaud M, Pasmant E.

Cancer Med. 2019 Jun 14. doi: 10.1002/cam4.2175. [Epub ahead of print]

2.

Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.

Wang H, Lekbaby B, Fares N, Augustin J, Attout T, Schnuriger A, Cassard AM, Panasyuk G, Perlemuter G, Bieche I, Vacher S, Selves J, Péron JM, Bancel B, Merle P, Kremsdorf D, Hall J, Chemin I, Soussan P.

Hepatol Int. 2019 May 28. doi: 10.1007/s12072-019-09950-7. [Epub ahead of print]

PMID:
31140152
3.

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E.

Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019.

4.

GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.

Gaujoux S, Parvanescu A, Cesaretti M, Silve C, Bieche I, Rebours V, Lévy P, Sauvanet A, Cros J.

Ann Surg Oncol. 2019 Apr 25. doi: 10.1245/s10434-019-07389-6. [Epub ahead of print]

PMID:
31025231
5.

Cortical branched actin determines cell cycle progression.

Molinie N, Rubtsova SN, Fokin A, Visweshwaran SP, Rocques N, Polesskaya A, Schnitzler A, Vacher S, Denisov EV, Tashireva LA, Perelmuter VM, Cherdyntseva NV, Bièche I, Gautreau AM.

Cell Res. 2019 Jun;29(6):432-445. doi: 10.1038/s41422-019-0160-9. Epub 2019 Apr 10.

PMID:
30971746
6.

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients.

Cabel L, Decraene C, Bieche I, Pierga JY, Bennamoun M, Fuks D, Ferraz JM, Lefevre M, Baulande S, Bernard V, Vacher S, Mariani P, Proudhon C, Bidard FC, Louvet C.

Cancers (Basel). 2019 Mar 21;11(3). pii: E396. doi: 10.3390/cancers11030396.

7.

Human Endothelial Colony Forming Cells Express Intracellular CD133 that Modulates their Vasculogenic Properties.

Rossi E, Poirault-Chassac S, Bieche I, Chocron R, Schnitzler A, Lokajczyk A, Bourdoncle P, Dizier B, Bacha NC, Gendron N, Blandinieres A, Guerin CL, Gaussem P, Smadja DM.

Stem Cell Rev. 2019 Mar 16. doi: 10.1007/s12015-019-09881-8. [Epub ahead of print]

PMID:
30879244
8.

A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.

Coussy F, de Koning L, Lavigne M, Bernard V, Ouine B, Boulai A, El Botty R, Dahmani A, Montaudon E, Assayag F, Morisset L, Huguet L, Sourd L, Painsec P, Callens C, Chateau-Joubert S, Servely JL, Larcher T, Reyes C, Girard E, Pierron G, Laurent C, Vacher S, Baulande S, Melaabi S, Vincent-Salomon A, Gentien D, Dieras V, Bieche I, Marangoni E.

Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32266. [Epub ahead of print]

PMID:
30859564
9.

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC.

Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.

PMID:
30715161
10.

Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis.

Cacheux W, Lièvre A, Richon S, Vacher S, El Alam E, Briaux A, El Botty R, Mariani P, Buecher B, Schnitzler A, Barbazan J, Roman-Roman S, Bièche I, Dangles-Marie V.

Int J Cancer. 2019 Feb 4. doi: 10.1002/ijc.32178. [Epub ahead of print]

PMID:
30714617
11.

Loss of the deglutamylase CCP5 perturbs multiple steps of spermatogenesis and leads to male infertility.

Giordano T, Gadadhar S, Bodakuntla S, Straub J, Leboucher S, Martinez G, Chemlali W, Bosc C, Andrieux A, Bieche I, Arnoult C, Geimer S, Janke C.

J Cell Sci. 2019 Feb 7;132(3). pii: jcs226951. doi: 10.1242/jcs.226951.

PMID:
30635446
12.

Interleukin-8 release by endothelial colony-forming cells isolated from idiopathic pulmonary fibrosis patients might contribute to their pathogenicity.

Blandinières A, Gendron N, Bacha N, Bièche I, Chocron R, Nunes H, Nevo N, Rossi E, Crestani B, Lecourt S, Chevret S, Lokajczyk A, Mignon V, Kisaoglu A, Juvin K, Bertil S, Valeyre D, Cras A, Gaussem P, Israël-Biet D, Smadja DM.

Angiogenesis. 2019 May;22(2):325-339. doi: 10.1007/s10456-018-09659-5. Epub 2019 Jan 3.

PMID:
30607696
13.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial.

Bernard-Tessier A, Jeannot E, Guenat D, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bièche I, Pierga JY, Buecher B, Meurisse A, François É, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S.

Clin Cancer Res. 2019 Apr 1;25(7):2109-2115. doi: 10.1158/1078-0432.CCR-18-2984. Epub 2018 Nov 30.

PMID:
30504426
14.

ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.

Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M, Mazel M, Cayrefourcq L, Geraci S, Vacher S, Pantano F, Filipits M, Driouch K, Bieche I, Gnant M, Jacot W, Aubin JE, Duterque-Coquillaud M, Alix-Panabières C, Clézardin P, Bonnelye E.

Oncogene. 2019 Feb;38(7):950-964. doi: 10.1038/s41388-018-0579-3. Epub 2018 Nov 26.

PMID:
30478447
15.

Distinct expression profiles and functions of Kindlins in breast cancer.

Azorin P, Bonin F, Moukachar A, Ponceau A, Vacher S, Bièche I, Marangoni E, Fuhrmann L, Vincent-Salomon A, Lidereau R, Driouch K.

J Exp Clin Cancer Res. 2018 Nov 26;37(1):281. doi: 10.1186/s13046-018-0955-4.

16.

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer.

Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I.

Mol Cancer Res. 2019 Feb;17(2):469-475. doi: 10.1158/1541-7786.MCR-18-0363. Epub 2018 Nov 6.

PMID:
30401719
17.

VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX.

Bonin F, Taouis K, Azorin P, Petitalot A, Tariq Z, Nola S, Bouteille N, Tury S, Vacher S, Bièche I, Rais KA, Pierron G, Fuhrmann L, Vincent-Salomon A, Formstecher E, Camonis J, Lidereau R, Lallemand F, Driouch K.

BMC Biol. 2018 Oct 2;16(1):109. doi: 10.1186/s12915-018-0576-6.

18.

Endothelial Colony-Forming Cells Do Not Participate to Fibrogenesis in a Bleomycin-Induced Pulmonary Fibrosis Model in Nude Mice.

Blandinières A, Gille T, Sadoine J, Bièche I, Slimani L, Dizier B, Gaussem P, Chaussain C, Planes C, Dorfmüller P, Israël-Biet D, Smadja DM.

Stem Cell Rev. 2018 Dec;14(6):812-822. doi: 10.1007/s12015-018-9846-5.

PMID:
30267203
19.

Precision medicine in oncology: what is it exactly and where are we?

Le Tourneau C, Kamal M, Bièche I.

Per Med. 2018 Sep;15(5):351-353. doi: 10.2217/pme-2018-0036. Epub 2018 Sep 27. No abstract available.

PMID:
30260312
20.

MT1-MMP targeting to endolysosomes is mediated by upregulation of flotillins.

Planchon D, Rios Morris E, Genest M, Comunale F, Vacher S, Bièche I, Denisov EV, Tashireva LA, Perelmuter VM, Linder S, Chavrier P, Bodin S, Gauthier-Rouvière C.

J Cell Sci. 2018 Sep 5;131(17). pii: jcs218925. doi: 10.1242/jcs.218925.

21.

Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.

Liang X, Vacher S, Boulai A, Bernard V, Baulande S, Bohec M, Bièche I, Lerebours F, Callens C.

Breast Cancer Res. 2018 Aug 7;20(1):88. doi: 10.1186/s13058-018-1007-x.

22.

Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.

Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.

Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.

PMID:
30075151
23.

Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function.

Castagnino A, Castro-Castro A, Irondelle M, Guichard A, Lodillinsky C, Fuhrmann L, Vacher S, Agüera-González S, Zagryazhskaya-Masson A, Romao M, El Kesrouani C, Noegel AA, Dubois T, Raposo G, Bear JE, Clemen CS, Vincent-Salomon A, Bièche I, Chavrier P.

Oncogene. 2018 Dec;37(50):6425-6441. doi: 10.1038/s41388-018-0422-x. Epub 2018 Jul 31.

PMID:
30065298
24.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.

Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.

PMID:
30054279
25.

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.

El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely JL, Leboucher S, Fouillade C, Vacher S, Ouine B, Cartier A, de Koning L, Cottu P, Bièche I, Marangoni E.

Oncotarget. 2018 Jul 3;9(51):29587-29600. doi: 10.18632/oncotarget.25640. eCollection 2018 Jul 3.

26.

ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.

Dumortier M, Ladam F, Damour I, Vacher S, Bièche I, Marchand N, de Launoit Y, Tulasne D, Chotteau-Lelièvre A.

Breast Cancer Res. 2018 Jul 11;20(1):73. doi: 10.1186/s13058-018-0992-0.

27.

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.

Br J Cancer. 2018 Aug;119(3):387. doi: 10.1038/s41416-018-0130-x.

28.

Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.

Arnedos M, Bayar MA, Cheaib B, Scott V, Bouakka I, Valent A, Adam J, Leroux-Kozal V, Marty V, Rapinat A, Mazouni C, Sarfati B, Bieche I, Balleyguier C, Gentien D, Delaloge S, Lacroix-Triki M, Michiels S, Andre F.

Ann Oncol. 2018 Aug 1;29(8):1755-1762. doi: 10.1093/annonc/mdy202.

PMID:
29893769
29.

The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.

Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely JL, Vacher S, Becette V, Caly M, Rapinat A, Gentien D, de la Grange P, Schnitzler A, Lallemand F, Marangoni E, Bièche I, Callens C.

J Pathol. 2018 Sep;246(1):103-114. doi: 10.1002/path.5104. Epub 2018 Aug 7.

PMID:
29876931
30.

The trimeric coiled-coil HSBP1 protein promotes WASH complex assembly at centrosomes.

Visweshwaran SP, Thomason PA, Guerois R, Vacher S, Denisov EV, Tashireva LA, Lomakina ME, Lazennec-Schurdevin C, Lakisic G, Lilla S, Molinie N, Henriot V, Mechulam Y, Alexandrova AY, Cherdyntseva NV, Bièche I, Schmitt E, Insall RH, Gautreau A.

EMBO J. 2018 Jul 2;37(13). pii: e97706. doi: 10.15252/embj.201797706. Epub 2018 May 29.

PMID:
29844016
31.

Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences.

Cacheux W, Tsantoulis P, Briaux A, Vacher S, Mariani P, Richard-Molard M, Buecher B, Richon S, Jeannot E, Lazartigues J, Rouleau E, Mariani O, El Alam E, Cros J, Roman-Roman S, Mitry E, Girard E, Dangles-Marie V, Lièvre A, Bièche I.

Cancer Med. 2018 May 26. doi: 10.1002/cam4.1533. [Epub ahead of print]

32.

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.

Spasojevic C, Marangoni E, Vacher S, Assayag F, Meseure D, Château-Joubert S, Humbert M, Karam M, Ricort JM, Auclair C, Regairaz M, Bièche I.

Oncotarget. 2018 May 1;9(33):23208-23219. doi: 10.18632/oncotarget.25292. eCollection 2018 May 1.

33.

First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.

Lehmann-Che J, Miquel C, Wong J, Callens C, Rouleau E, Quillien V, Lozano N, Cayre A, Lacroix L, Bieche I, Bertheau P, Teixeira L, Llorca FP, Lamy PJ, DE Cremoux P; GFCO GROUP.

Anticancer Res. 2018 May;38(5):2909-2914.

PMID:
29715116
34.

Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.

Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E, Le Gal D, Girard E, Popova T, La Rosa P, Beauvallet J, Eon-Marchais S, Dondon MG, d'Enghien CD, Laugé A, Chemlali W, Raynal V, Labbé M, Bièche I, Baulande S, Bay JO, Berthet P, Caron O, Buecher B, Faivre L, Fresnay M, Gauthier-Villars M, Gesta P, Janin N, Lejeune S, Maugard C, Moutton S, Venat-Bouvet L, Zattara H, Fricker JP, Gladieff L, Coupier I; CoF-AT; GENESIS; kConFab, Chenevix-Trench G, Hall J, Vincent-Salomon A, Stoppa-Lyonnet D, Andrieu N, Lesueur F.

Breast Cancer Res. 2018 Apr 17;20(1):28. doi: 10.1186/s13058-018-0951-9.

35.

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M.

ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018.

36.

High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.

Bataillon G, Fuhrmann L, Girard E, Menet E, Laé M, Capovilla M, Treilleux I, Arnould L, Penault-Llorca F, Rouzier R, Marchiò C, Bieche I, Vincent-Salomon A.

Histopathology. 2018 Aug;73(2):273-283. doi: 10.1111/his.13514. Epub 2018 May 7.

37.

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I.

Anticancer Res. 2018 Mar;38(3):1485-1490.

PMID:
29491076
38.

Involvement of the FOXO6 transcriptional factor in breast carcinogenesis.

Lallemand F, Petitalot A, Vacher S, de Koning L, Taouis K, Lopez BS, Zinn-Justin S, Dalla-Venezia N, Chemlali W, Schnitzler A, Lidereau R, Bieche I, Caputo SM.

Oncotarget. 2017 Dec 30;9(7):7464-7475. doi: 10.18632/oncotarget.23779. eCollection 2018 Jan 26.

39.

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O'Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S.

J Clin Oncol. 2018 Apr 1;36(10):981-990. doi: 10.1200/JCO.2017.74.8301. Epub 2018 Feb 22.

40.

Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome.

Kamal M, Tarcic G, Dureau S, Edelheit O, Barbash Z, Lecerf C, Morel C, Miron B, Callens C, Servant N, Bieche I, Vidne M, Le Tourneau C.

Mol Oncol. 2018 May;12(5):594-601. doi: 10.1002/1878-0261.12180. Epub 2018 Mar 30.

41.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

42.

Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.

Cacheux W, Dangles-Marie V, Rouleau E, Lazartigues J, Girard E, Briaux A, Mariani P, Richon S, Vacher S, Buecher B, Richard-Molard M, Jeannot E, Servant N, Farkhondeh F, Mariani O, Rio-Frio T, Roman-Roman S, Mitry E, Bieche I, Lièvre A.

Oncotarget. 2017 Dec 8;9(1):464-476. doi: 10.18632/oncotarget.23066. eCollection 2018 Jan 2.

43.

Involvement of Aryl hydrocarbon receptor in myelination and in human nerve sheath tumorigenesis.

Shackleford G, Sampathkumar NK, Hichor M, Weill L, Meffre D, Juricek L, Laurendeau I, Chevallier A, Ortonne N, Larousserie F, Herbin M, Bièche I, Coumoul X, Beraneck M, Baulieu EE, Charbonnier F, Pasmant E, Massaad C.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1319-E1328. doi: 10.1073/pnas.1715999115. Epub 2018 Jan 19.

44.

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.

Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, Klijanienko J, Mariani O, Jouffroy T, Calugaru V, Hoffmann C, Lesnik M, Badois N, Berger F, Le Tourneau C, Kamal M, Bieche I.

Eur J Cancer. 2018 Mar;91:47-55. doi: 10.1016/j.ejca.2017.12.016. Epub 2018 Jan 11.

PMID:
29331751
45.

High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism.

Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M.

PLoS One. 2018 Jan 10;13(1):e0190619. doi: 10.1371/journal.pone.0190619. eCollection 2018.

46.

Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.

Dos Santos ES, Caputo SM, Castera L, Gendrot M, Briaux A, Breault M, Krieger S, Rogan PK, Mucaki EJ, Burke LJ; ENIGMA consortium, Bièche I, Houdayer C, Vaur D, Stoppa-Lyonnet D, Brown MA, Lallemand F, Rouleau E.

Breast Cancer Res Treat. 2018 Apr;168(2):311-325. doi: 10.1007/s10549-017-4602-0. Epub 2017 Dec 13.

PMID:
29236234
47.

Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness.

Bogeas A, Morvan-Dubois G, El-Habr EA, Lejeune FX, Defrance M, Narayanan A, Kuranda K, Burel-Vandenbos F, Sayd S, Delaunay V, Dubois LG, Parrinello H, Rialle S, Fabrega S, Idbaih A, Haiech J, Bièche I, Virolle T, Goodhardt M, Chneiweiss H, Junier MP.

Acta Neuropathol. 2018 Feb;135(2):267-283. doi: 10.1007/s00401-017-1783-x. Epub 2017 Nov 17.

48.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I.

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

49.

Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.

Br J Cancer. 2017 Dec 5;117(12):1819-1827. doi: 10.1038/bjc.2017.353. Epub 2017 Oct 12. Erratum in: Br J Cancer. 2018 Aug;119(3):387.

50.

Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.

Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C, Deniziaut G, Melaabi S, Ng CCK, Marchiò C, Rouzier R, Bièche I, Vincent-Salomon A.

Mod Pathol. 2018 Jan;31(1):68-82. doi: 10.1038/modpathol.2017.107. Epub 2017 Sep 8.

Supplemental Content

Loading ...
Support Center